Scott Biller, chief scientific officer of Agios Pharmaceuticals (NASDAQ: [[ticker:AGIO]]) since 2010, is retiring at the end of this year. The Cambridge, MA-based company said that Biller will continue as an advisor through the end of 2020. Agios, which develops drugs to treat cancer and rare diseases, is searching for Biller’s successor. Last year, Agios won FDA approval for ivosidenib (Tibsovo), a drug that treats acute myeloid leukemia.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
